The differences that matter for peptide users: absorption, comfort, site selection, and which protocols call for which route.
Most research peptides are administered subcutaneously (SC) — a few are typically intramuscular (IM). The difference is more practical than dramatic, but it matters enough to understand before you pick a site.
Subcutaneous injection means delivering into the fat layer just under the skin. For most peptides:
Most BPC-157, GHK-Cu, semaglutide, ipamorelin, CJC-1295, and similar peptides default to SC.
Intramuscular injection delivers into the muscle. For peptides:
TB-500 and a few longer-acting peptides are sometimes administered IM in self-reports. Whether IM offers any real advantage over SC for those compounds is debated.
The classic SC sites:
Rotate sites to avoid scar tissue. Peptide IA lets you log site per dose so you do not pile injections in one spot.
If you are doing IM, the safer sites for self-administration are:
The gluteal site is more complex due to nearby nerves and is harder to do safely on yourself. Skip it unless trained.
Inexperienced self-administered IM injections carry more risk than SC. If you are not confident, do not improvise.
SC injections occasionally bruise — usually from hitting a small superficial vessel. Apply a cold compress for a minute after withdrawal if it stings.
IM injections rarely bruise but can ache for hours. Reduce by:
The single biggest reduction in infection risk is one clean needle per dose.
When in doubt: SC. It is the safer, more comfortable, more forgiving route.
Peptide IA is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.